Orakl Oncology, a Paris, France-based precision oncology company, raised €11M in Seed funding.
The round was led by Singular, with participation from Bpifrance including the Grand Prix i-Lab, and existing investors.
Founded in 2023 by Fanny Jaulin, PhD, Diane-Laure Pagès, PhD, and Gustave Ronteix, PhD, Orakl is a spin-off from the Gustave Roussy Institute, an European cancer research institute. The company has developed an AI-powered techbio platform that combines real-world patient data with biology into an integrated decision-making engine for the entire drug development process. Orakl’s technology delivers predictions to improve the recruitment of responding patients and clinical trial probability of success.
The company intends to use the funds to accelerate its growth and support the launch of two new commercial products, O-Predict and O-Validate, for oncology drug development.
FinSMEs
03/12/2024